Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Unicycive Therapeutics (UNCY) Total Non-Current Liabilities (2022 - 2026)

Unicycive Therapeutics filings provide 3 years of Total Non-Current Liabilities readings, the most recent being $5.3 million for Q4 2024.

  • On a quarterly basis, Total Non-Current Liabilities rose 8.94% to $5.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was $5.3 million, a 8.94% increase, with the full-year FY2024 number at $5.3 million, up 8.94% from a year prior.
  • Total Non-Current Liabilities hit $5.3 million in Q4 2024 for Unicycive Therapeutics, up from $4.3 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $5.7 million in Q1 2024 to a low of -$7.1 million in Q4 2022.
  • Median Total Non-Current Liabilities over the past 3 years was $4.5 million (2023), compared with a mean of $3.3 million.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 168.62% in 2023 and later dropped 2.97% in 2024.
  • Unicycive Therapeutics' Total Non-Current Liabilities stood at -$7.1 million in 2022, then surged by 168.62% to $4.9 million in 2023, then grew by 8.94% to $5.3 million in 2024.
  • The last three reported values for Total Non-Current Liabilities were $5.3 million (Q4 2024), $4.3 million (Q3 2024), and $5.2 million (Q2 2024) per Business Quant data.